BioAge Labs, Inc.
Case Overview
49 Days Left to Seek Lead Plaintiff
Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 03/10/2025 |
Status: | Status: Investigating |
Company Name: | Company Name: BioAge Labs, Inc. |
Court: | Court: Northern District of California |
Case Number: | Case Number: 3:25cv00196 |
Class Period: | Class Period: 09/22/2024 - 01/07/2025 |
Ticker: | Ticker: BIOA |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired BioAge Labs, Inc. (“BioAge” or the “Company”) (NASDAQ:BIOA) securities during the period from September 22, 2024, through January 7, 2025 (“the Class Period”). Investors have until March 10, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.
On September 27, 2024, BioAge completed its initial public offering (“IPO”), selling 12.65 million shares at $18 per share. The Company’s IPO documents discussed its collaboration with Eli Lilly and Company in connection with its ongoing STRIDES clinical trial of BioAge’s lead product candidate, azelaprag, in combination with GLP-IR agonists to establish proof of concept for enhanced weight loss.
Less than 3 months after its IPO, on December 6, 2024, BioAge announced that it discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns, after liver transaminitis was observed in subjects receiving azelaprag. BioAge stated that the decision to discontinue the STRIDES Phase 2 study of azelaprag “became clear” due to “the emerging safety profile of the current doses tested.” On this news, the price of BioAge stock fell by $15.44 per share, or approximately 76%, from $20.09 per share on December 6, 2024, to close at $4.65 on December 9, 2024.
The complaint alleges that defendants, in the IPO documents and throughout the Class Period, made false and/or materially misleading information regarding its STRIDES Phase 2 clinical trial.
On September 27, 2024, BioAge completed its initial public offering (“IPO”), selling 12.65 million shares at $18 per share. The Company’s IPO documents discussed its collaboration with Eli Lilly and Company in connection with its ongoing STRIDES clinical trial of BioAge’s lead product candidate, azelaprag, in combination with GLP-IR agonists to establish proof of concept for enhanced weight loss.
Less than 3 months after its IPO, on December 6, 2024, BioAge announced that it discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns, after liver transaminitis was observed in subjects receiving azelaprag. BioAge stated that the decision to discontinue the STRIDES Phase 2 study of azelaprag “became clear” due to “the emerging safety profile of the current doses tested.” On this news, the price of BioAge stock fell by $15.44 per share, or approximately 76%, from $20.09 per share on December 6, 2024, to close at $4.65 on December 9, 2024.
The complaint alleges that defendants, in the IPO documents and throughout the Class Period, made false and/or materially misleading information regarding its STRIDES Phase 2 clinical trial.